Search

Your search keyword '"Guidi, Luisa"' showing total 463 results
Start Over Author "Guidi, Luisa"
463 results on '"Guidi, Luisa"'

1. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Author

Gornet, Jean-Marc, Beaugerie, Laurent, Shaji, Sebastian, Peyrin-Biroulet, Laurent, Reimund, Jean-Marie, Hebuterne, Xavier, Amiot, Aurélien, Armelao, Franco, Blanc, Pierre, Papi, Claudio, De Chambrun, Guillaume Pineton, Roblin, Xavier, Chu, Karmiris, Konstantinos, Shariq, Sohail, Viazis, Nikolaos, Limdi, Jimmy, Eder H, Piotr, Michalopoulos, Georgios, Bell, Andrew, Biancone, Livia, Dewitte, Marie, Mazhar, Zia, Franchimont, Denis, Nancey, Stephane, Macaigne, Gilles, Principi, Maria Beatrice, Fumery, Mathurin, Parkes, Gareth, Valats, Jean-Christophe, Doherty, Glen, Bouguen, Guillaume, Molnar, Tamás, Tsai, Hersin, Gangi, Mohsin, Pedersen, Natalia, Heluwaert, Frédéric, Shenderey, Richard, Zeissig, Sebastian, Butterworth, Jeffrey, Castiglione, Fabiana, Corless, Lynsey, Zallot, Camille, Baert, Filip, Singh, Salil, Sonwalkar, Sunil, Clayton, Elizabeth, Rahier, Jean-François, Vani, Deven, Bellaiche, Guy, De Vos, Martine, Kirchgesner, Julien, Kopylov, Uri, Lobaton, Triana, Locher, Christophe, Mantzaris, Gerassimos, Abouda, George, Smith, Katie, Sprakes, Michael, Theodoropoulou, Angeliki, Wesley, Emma, Bonnet, Joëlle, Elphick, David, Gilletta, Cyrielle, Gordon, John, Laharie, David, Nakad, Antoine, Orlando, Ambrogio, Dubois, Patrick, Hasselblatt, Peter, Michiels, Christophe, Preston, Cathryn, Staicu, Anca, Vuitton, Lucine, Kaassis, Mehdi, Speight, Ally, Ghosh, Deb, Löwenberg, Mark, Mathieu, Nicolas, Pelletier, Anne-Laure, Phillips, Anne, Magro, Fernando, Altwegg, Romain, Avni, Irit, biron, Landy, Jonathon, Nachury, Maria, Shenoy, Achuth, Trang, Caroline, Abitbol, Vered, Bamias, Georgios, Farkas, Klaudia, Maaser, Christian, Shitrit, Ariella, Siegmund, Britta, Filippi, Jérôme, O'morain, Colm, Yanai, Henit, Costes, Laurent, Hobday, David, Szepes, Zoltán, Calabrese, Emma, Dallal, Helen, Fung, Michael, Ramadas, Arvind, Baburajan, Bijay, Koss, Konrad, Barberis, Christophe, Buisson, Anthony, Amil, Morgane, Balestrieri, Paola, Johnson, Matthew, Tzouvala, Maria, Viennot, Stéphanie, Nagy, Ferenc, Thompson, Nick, Alric, Laurent, Samuel, Sunil, Bourrier, Anne, Chanteloup, Elise, Del Tedesco, Emilie, Harbord, Marcus, Lobo, Alan, Myers, Sally, Pollok, Richard, Ahmad, Tariq, Chaudhary, Rakesh, Karakoidas, Christos, Soliman, Ashraf, Stefanescu, Carmen, Theocharis, Georgios, Branden, Stijn Vanden, Beltran, Belén, Bouhnik, Yoram, Bourreille, Arnaud, Branco, Joana, Colleypriest, Ben, Eliakim, Rami, Knight, Paul, O'toole, Aoibhlinn, Robles, Virgina, Triantafyllou, Konstantinos, Bosca, Marta Maia, Lambrecht, Guy, Mosquera, Lucia Marquez, Panter, Simon, Pappa, Aikaterini, Simon, Marion, Sivaji, Ganesh, Bellanger, Christophe, Belle, Arthur, Borruel, Natalia, Egan, Laurence, Peeters, Harald, Sharpstone, Daniel, Arasaradnam, Ramesh, Benitez, José Manuel, Dahlerup, Jens Frederik, Giouleme, Olga, Gisbert, Javier P., Helwig, Ulf, Minguez, Miguel, Tsironi, Eftychia, Variola, Angela, Allen, Patrick, Boivineau, Lucille, Cole, Andy, Dib, Nina, Gomollon, Fernando, Johnston, Richard, Katsanos, Konstantinos, Kennedy, Nick, Kiszka-Kanowitz, Marianne, Marin-Jimenez, Ignacio, Miheller, Pál, Nos, Pilar, Saraj, Othman, Vinter-Jensen, Lars, Zittan, Eran, Baudry, Clotilde, Calvet, Xavier, Cazelles-Boudier, Marie-Christine, Coenegrachts, Jean-Louis, Cullen, Garret, Daperno, Marco, Dhar, Anjan, Gerard, Romain, Jensen, Nanna, Maharshak, Nitsan, Mcalindon, Mark, Mcloughlin, Simon, Parkes, Miles, Patel, Kamal, Peixoto, Armando, Polymeros, Dimitrios, Portela, Francisco, Rocca, Rodolfo, Seksik, Philippe, Subramanian, Sreedhar, Tennenbaum, Ruth, Atreya, Raja, Bachmann, Oliver, Berger, Arthur, Bor, Renáta, Buckley, Maire, Carpio, Daniel, Chaparro, María, Costa, Francesco, Domenech, Eugeni, Esteve, Maria, Foley, Stephen, Guardiola, Jordi, Koutroubakis, Ioannis, Kuehbacher, Tanja, Landman, Cécilia, Lavagna, Alessandro, Manceñido, Noemí, Mañosa, Míriam, Martín-Arranz, Maria Dolores, Plastaras, Laurianne, Scribano, Maria Lia, Sengupta, Subhasish, Teich, Nils, Tran-Minh, My-Linh, Zampeli, Evanthia, Amininejad, Leila, Arroyo, Teresa, Attar, Alain, Backman, Ann-Sofie, Bálint, Anita, Beckly, John, Ben Horin, Shomron, Bernardo, Sónia, Caillo, Ludovic, Caron, Bénédicte, Shanika de Silva, María, FábiáN, Anna, Fiorino, Gionata, Gutierrez, Ana, Lahat, Adi, Masmoudi, Mohamed, Mendolaro, Marco, Muls, Vinciane, Poullenot, Florian, Probert, Christopher, Reenaers, Catherine, Rutka, Mariann, Sarwari, Zaman, Sayer, Joanne, Sicilia, Beatriz, Sousa, Helena, van Kemseke, Catherine, Zabana, Yamile, Astegiano, Marco, Banim, Paul, Bettenworth, Dominik, Boualit, Médina, Brodersen, Jacob Broder, Christidou, Angeliki, Cooney, Rachel, Pinto, João Cortez, Cravo, Portugal Marília, Cremer, Anneline, Danese, Silvio, di Sabatino, Antonio, Fallingborg, Jan, Ferronato, Antonio, Planella, Esther Garcia, Gupta, Sanjay, Halfvarson, Jonas, Israeli, Eran, Kestenbaum, Samantha, Larsen, Lone, Macken, Elisabeth, Mathou, Nicoletta, Milassin, Ágnes, Pofelski, Joanna, Ricci, Chiara, Rodriguez-Moranta, Francisco, Schmidt-Lauber, Martin, Shaw, Ian, Soares, Marta, Soliman, Heithem, Triantos, Christos, Zografos, Konstantinos, Agrawal, Anurag, Armuzzi, Alessandro, Aubourg, Alexandre, Acosta, Manuel Barreiro-de, Barrio, Jesús, Bergemalm, Daniel, Bermejo, Fernando, Bodini, Giorgia, Bohr, Johan, Bossuyt, Peter, Christodoulou, Dimitrios, Claessens, Christophe, Collins, Paul, de Francisco, Ruth, Garcia, Santiago, Georgopoulos, Sotirios, Goutorbe, Felix, Kalantzis, Chrisostomos, Kourikou, Anastasia, Mace, Vincent, Malamut, Georgia, Ministro, Paula, Larmurier, Isabelle Nion, Ricart, Elena, Serrero, Mélanie, Sheridan, Juliette, Weimers, Petra, Andersen, Vibeke, Arroja, Bruno, Bokemeyer, Bernd, Bujanda, Luis, Degand, Thibault, Eriksson, Carl, Garceau, Cécile, Glerup, Henning, Goren, Idan, Jackson, Lucina, Koch, Stéphane, Mesonero, Francisco, Ordas, Ingrid, Riviere, Pauline, Saibeni, Simone, Soares, João, Tavernier, Noémie, Theede, Klaus, Ungar, Bella, Bästlein, Elke, Gasbarrini, Antonio, Protopapas, Andreas, Reindl, Wolfgang, Bossa, Fabrizio, Hart, Ailsa, Heil, Franz-Josef, O'Connor, Anthony, Oldenburg, Bas, Pastorelli, Luca, Stephen patchett, Ramakrishnan, Subramaniam, de Caestecker, John, Echarri, Ana, Kevans, David, Büning, Jürgen, Coelho, Rosa, Jansen, Jeroen, Koslowski, Benjamin, Wells, Christopher, Ceballos, Daniel, König, Ingrid, Padmanabhan, Hari, Patani, Timi, Qureshi, Raheel, Zagorowicz, Edyta, Allez, Matthieu, Archavlis, Emmanouil, Bonnet, Delphine, Guidi, Luisa, Mcnamara, Deirdre, Vernia, Piero, Weidenhiller, Michael, Alon, Lang, Boysen, Trine, Delattre, Charlotte, Farrell, Richard, Krüger, Rolf-Achim, Paupard, Thierry, Vind, Ida, Caprioli, Flavio, Gancho, Vladimir, Quentin, Vincent, Avidan, Benjamin, D’Haens, Geert, Mccarthy, Jane, Snook, Jonathon, Soufleris, Konstantinos, Zerbib, Frank, Carter, Dan, Depla, Annekatrien, Eisenbach, Thomas, Fries, Walter, Grammatikos, Nikolaos, Ilegems, Saskia, Lopez-Sanroman, Antonio, Moreau, Jacques, Riegler, Gabriele, Rietdijk, Svend, Rocha, Marta, Rosa, Isabelle, Ryan, Barbara, Yeremenko, Yelena, Boruchowicz, Arnaud, Damião, Filipe, Laoudi, Foteini, Lügering, Andreas, Macarri, Giampiero, Thomopoulos, Konstantinos, Barros, Luísa, Blixt, Thomas, Garros, Aurélien, Khorrami, Sam, Sokol, Harry, Sturm, Andreas, Livovsky, Dan, Maul, Jochen, Miks, Heinrich, Papadopoulos, Vasileios, Schmidt, Carsten, Snir, Yifat, Svenningsen, Lise, Ahmed, Wafaa, Broitman, Yelena, Cuillerier, Emmanuel, Kant, Prashant, Leyden, Jan, Lichtenstein, Lev, Lopes, Susana, Martineau, Chloé, Mulcahy, Hugh, Schweitzer, Axel, Van Schaik, Fiona, Banai, Hagar, Danion, Pauline, Dulery, Charlotte, Fidder, Herma, Gay, Claire, Hagege, Hervé, Harnois, Florence, Jørgensen, Søren Peter, Müller-Ziehm, Jens, Oikonomou, Michail, Palmela, Carolina, Schulze/Röske, Jörg, Smith, Mark, Thurm, Tamar, Bresso, Francesca, Brixi, Hedia, Jones, John, Macmathuna, Padraig, Painchart, Claire, Ron, Yulia, Vester-Andersen, Marianne, Alexandrino, Gonçalo, Börner, Norbert, Cardoso, Mariana, Chagas, Cristina, Dignaß, Axel, Dotan, Iris, Hedin, Charlotte, Karatzas, Pantelis, Kasapidis, Panagiotis, Palatka, Károly, Sakizlis, Georgios, Wilson, Ana, Bosanko, Nick, Caldeira, Paulo, Gagniere, Charlotte, Libier, Louise, Meunier, Camille, Moog, Gero, Pasquion, Audrey, Pica, Roberta, Akbar, Ayesha, Arab, Nadia, Cadiot, Guillaume, Carvalho, João, Charpignon, Claire, Fellermann, Laus, Fishman, Sigal, Fraser, Gerald, Gluck, Nathan, Hoesl, Mark, Kierkus, Jarosław, Klopocka, Maria, Arranz, Eduardo Martin, Menchen, Luis, Nikolaus, Susanna, Petrache, Anca, Ponsioen, Cyriel, Riestra, Sabino, Robledo, Pilar, Rodriguez, Cristina, Samer, Misheal, Tischer, Matthias, Wypych, Joanna, Baudon, Julien, Bezzio, Cristina, Boschetti, Gilles, Burisch, Johan, Creed, Tom, Demarzo, Maria Giulia, Festa, Stefano, Figueroa, Andrés, Julsgaard, Mette, Navarro, Pablo, Perez-Galindo, Pablo, Rouillon, Cléa, Sablich, Emanuele, Tosca, Joan, Vidon, Mathias, Vidon, Marine, Vitte, René-Louis, Wampach, Anne, Baumann, Cédric, Urmes, Isabelle Clerc, Rousseau, Hélène, Borie, Marc, Uzzan, Mathieu, Chatten, Kelly, Peter, Rimmer, Tariq, Iqbal, Cossignani, Marta, Cañete, Fiorella, Holvoet, Tom, Krasz, Susanne, Dias, Sandra, Abalia, Hadas, Abaza, Aziza, Abramovich, Gal, Ackzell, Ingrid, Adams, Carol, Addleton, Catherine, Alfambra, Erika, Algaba, Alicia, Allcock, Clare, Allison, Joanna, Amouriaux, Karine, Anderson, Julie, Anderson, Emma, Appelmans, Saskia, Armstrong, Lisa, Atkins, Stacey, Attaran-Bandarabadi, Masoumeh, Bailey, Yvonne, Bardot, Stephanie, Beck, Natasha, Bennett, Lillie, Bergfeld, Jonathan Phil, Berkane, Ramdane, Boey, Hanne, Bowlas, Louise, Bradley-Potts, Joanne, Brear, Tracy, Bretlander-Peters, Nicole, Brown, Ellen, Brown, Johanna, Buckingham, Elizabeth, Buellens, Katrien, Bull, Rhian, Burke, Maura, Burns, Leighanne, Burton, Julie, Bwalya, Agness, Cabanas, Karine, Callaghan, Muriel, Camou, Océane, Campbell, Debbie, Capoferro, Elvira, Carnahan, Mandy, Carnio, Cornelia, Carter, Anne, Clack, Concetta Casali, Chedouba, Leïla, Cipriano, Bessie, Claeys, Sophie, Closset, Manon, Coban, Dilek, Cococcia, Sara, Coe, Carolann, Cole, Helen, Collet, Emilie, Collins, Kayleigh, Combes, Isabelle, Connor, Emma, Constantin, Kathryn, Cooke, Susan, Cornet, Nathanaëlle, Corrihons, Estelle, Corsino, Pilar, Cortaville, Rosie, Cotterill, Donna, Cowton, Amanda, Cox, Harriet, Cripps, Viktoria, Crowder, Amanda, Cukier, Tzufit, Daniel, Amelia, Dawe, Chris, de Haan, Jose, Croix, Rosanna de la, Dejonckheere, Evva, Villanegro, Juan Delare, Delaval, Guillaume, Delliponti, Mariangela, Delommez, Aude, Detry, Emilie, Dhanaratne, Melanie, Galan, Laura Diez, Dodel, Marie, Dooks, Emma, Du Cheyron, Joseph, Duane, Linda, Vulgo Cochran, Jennifer Dulling, Dyer, Simona, Dymond, Harvey, Ekblad, Charlotte, Elliott, Kerry, Emmerson, Ingrid, Eugene-Jolchine, Irène, Fleming, Lorna, Fletcher, Eve, Ford, Sarah, Forshaw, Greg, Foulds, Angela, Francois, Caroline, Fuge, Nicole, Gafni, Gal, Ganon, Miri, Nuñez, Olga Garcia, Ramirez, Laura Garcia, Gelder, Sophie, Gettkowski, Raimonda, Gilardi, Daniela, Giuffrida, Paolo, Gobert, Vincent, Godden, Jo, Godwin, Nuala, Goulden, Kay, Graham, Sharon, Green, Charlotte, Green, Marie, Gueye, Aboubakar, Guler, Tuba, Gustavsson, Ida, Hadjisavvas, Helena, Hammonds, Fiona, Hantzi, Christina, Hauke, Marion, Haydock, Julie, Hayes, Orla, Nislev, Lizette Helbo, Hochstodter, Jessica, Hogg, Ashleigh, Hölbing, Manuela, Holland, Maureen, Holsbergen, Maartje, Howard, Linda, Hoyda, Aviya, Hull, Robert, Irish, Jane, Jackson, Wendy, Janssen, Wendy, Jeffrey, Lesley, Jourdan, Sofia, Jutrowska, Izabela, Kaniel, Chava, Karezos, Theofilos, Kelly, Niamh, Kelly, Jessica, Kennedy, Mary, Kennedy, Una, Kibaru, Joyce, Kirkman, Gemma, Klaproth, Janine, Kneese, Corinna, Koch, Andrea, Kokke, Kathleen, Koppelow, Martha, Krause, Sabine, Krauspe, Sabine, Kwakkenbos, Petra, Labarile, Nunzia, Lang, Hannah, Lassailly, Marianne, Leconte, Martine, Lepczynski, Linda, Levell, Emma, Levhar, Nina, Lindhort, Kerstin, Lisle, Jessica, Cauce, Beatriz Lopez, Lorenz, Gabriele, Lovati, Ambra, Lowry, Tracey, Lund, Margareta, Vorderbrügge, Anne Lutz, Maansson, Suzanne, Madapathage, Videsheka, Cheviakoff, Maelys, Magness, Alison, Manley, Orla, Manyoni, Catherine, Marg, Ingke, Marra, Antonella, Martins, Carole, Massella, Arianna, Mathias, Aurore, Mervyn, Danielle, Minsart, Charlotte, Mitchell, Sally, Monks, Kathleen, Montero, Mélanie, Moore, Alson, Moser, Maren, Moss, Alison, Mullen, Angela, Murciano, M. Francisca, Naylor, Deanna, Nehus, Ansgar, Nicholson, Anne, Nöding, Sarah, Nolan, Sinead, Nörenberg, Janet, Northcott, Clare, O'Connell, Jim, O’Kelly, Alison, Orbach-Zingboim, Noam, Orobitg, Judit, Otieno, Charlene, Owen, Charlotte, Patch, Sarah, Pauker, Maor, Pauli, Renate, Pearson, Harriet, Peggy, Falgon, Petit, Séverine, Petrissans, Christine, Piergallini, Simona, Pippard, Lucy, Pitt, Laura, Pócsik, Gabriella, Poher, Yoann, Pomes, Chloé, Pritchard, Lucy, Puchades, Laura, Quaid, Sheena, Rana, Aleem, Raynard, Dana, Reilly, Mykla, Reinert, Sonja, Reinknecht, Manuela, Renner, Baerbel, Reynolds, Rob, Rizzuto, Giulia, Robinson, Matthew, Robrechts, Joke, Rodriguez, Eva M., Rosenblum, Efrat, Russel, Tamlyn, Sadare, Ibiyemi, Salama, Noa, Schakel, Toos, Schauer, Anja, Schiavoni, Elisa, Shaw, Caroline, Shelton, Sarah, Sicart, Virginie, Siouville, Elodie, Smith, Orla, Soude, Théo, Stephenson, Sophie, Stephenson, Elaine, Steppe, Marjan, Sterkx, An, Stickley, Jo, Sugrue, Kathleen, Swietec, Natalia, Tasiaux, Charlotte, Thamu, Bhavneet, Thomas, Susane, Tobi, Ogwa, Touabi, Kahina, Tovi, Shifra, Tregonning, Julie, Turchini, Laura, Unkhoff, Julia, Unruh, Olesya, Uzun, Nurcan, Van Aert, Frauke, Bergh, Sandrine Vanden, Vandenbroucke, Louise, Vansteenkiste, Laura, Vardit, Shay, Vergriete, Valentin, Walker, Elaine, Warner, Eleanor, Watchorn, Olivia, Watson, Ekaterina, Wauthier, Marie-Claire, Weetman, Belgium Maria, Weston, Margaret, West-Petroschka, Wiebke, Wienecke, Susann, Wierling, Kerstin, Wiestler, Miriam, Wilcox, Rebecca, Wilhelmsen, Elva, Williams, Angharad, Williamson, Georgina, Wilson, Deborah, Wistance, Kate, Wortmann, Nicolas, Wurie, Subie, Yadgar, Karin, Young, Gail, Young, Megan, Aucouturier, Julien, Bertin, Marie- Jo, Bougrine, Hasnae, Coisnon, Marie, Defrance, Antoine, Gutierrez, Kati, Harouz, Amel, Jerber, Laure, Khlifi, Aida, Kirati, Amina, Liworo, Nasaladjine, Logoltat, Maude, Mailhat, Charlotte, M'Bayi, Chancely, Medane, Yasmina, Merkhoufa, Dalal, Elhad, Saouda Mohamed, Monthe, Bertille, Moyon, Fanny, Rabiega, Pascaline, Sekela, Jennifer, Thilloy, Charlotte, Hamamouche, Naima, Partisotti, Frederic, Blandin, Patrick, Mokhtari, Hocine, Coutard, Laure, and Doherty, Glen A.

Published
2023
Full Text
View/download PDF

2. Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease:Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies

Author

Ten Bokkel Huinink, Sebastiaan, Thomassen, Doranne, Steyerberg, Ewout W., Pauwels, Renske W.M., Casanova, Maria J., Bouguen, Guillaume, Mak, Joyce W.Y., Molnár, Tamas, Lobo, Alan J., Seidelin, Jacob B., Amiot, Aurelien, D'Haens, Geert, Rivière, Pauline, Guidi, Luisa, Bor, Renata, Lin, Wei Chen, Peyrin-Biroulet, Laurent, Gisbert, Javier P., Janneke van der Woude, C., de Vries, Annemarie C., Ten Bokkel Huinink, Sebastiaan, Thomassen, Doranne, Steyerberg, Ewout W., Pauwels, Renske W.M., Casanova, Maria J., Bouguen, Guillaume, Mak, Joyce W.Y., Molnár, Tamas, Lobo, Alan J., Seidelin, Jacob B., Amiot, Aurelien, D'Haens, Geert, Rivière, Pauline, Guidi, Luisa, Bor, Renata, Lin, Wei Chen, Peyrin-Biroulet, Laurent, Gisbert, Javier P., Janneke van der Woude, C., and de Vries, Annemarie C.

Abstract

BACKGROUND: The risk of relapse after anti-tumour necrosis factor [TNF] therapy discontinuation in Crohn's disease patients with perianal fistulas [pCD] is unclear. We aimed to assess this risk. METHODS: A systematic literature search was conducted to identify cohort studies on the incidence of relapse following anti-TNF discontinuation in pCD patients. Individual participant data were requested from the original study cohorts. Inclusion criteria were age ≥16 years, pCD as a (co)indication for start of anti-TNF therapy, more than three doses, and remission of luminal and pCD at anti-TNF discontinuation. The primary outcome was the cumulative incidence of CD relapse using Kaplan-Meier estimates. Secondary outcomes included response to re-treatment and risk factors associated with relapse as assessed by Cox regression analysis. RESULTS: In total, 309 patients from 12 studies in ten countries were included. The median duration of anti-TNF treatment was 14 months [interquartile range 5.8-32.5]. Most patients were treated for pCD without active luminal disease [89%], received first-line anti-TNF therapy [87%], and continued immunomodulatory therapy following anti-TNF discontinuation [78%]. The overall cumulative incidence of relapse was 36% (95% confidence interval [CI] 25-48%) and 42% [95% CI 32-53%] at 1 and 2 years after anti-TNF discontinuation, respectively. Risk factors for relapse included smoking (hazard ratio [HR] 1.5 [1.0, 2.1]) and history of proctitis (HR 1.7 [1.1, 2.5]). The overall re-treatment response rate was 82%. CONCLUSIONS: This individual participant data meta-analysis, on predominantly patients with pCD without active luminal disease and first-line anti-TNF therapy, shows that over half of patients remain in remission 2 years after anti-TNF discontinuation. Therefore, anti-TNF discontinuation may be considered in this subgroup.

Published
2024

5. Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis

Author

Cerrito, Lucia, Guidi, Luisa, Vecchio, Fabio Maria, Miele, Luca, Guidi, Luisa (ORCID:0000-0003-3320-7094), Vecchio, Fabio M (ORCID:0000-0002-9197-2264), Miele, Luca (ORCID:0000-0003-3464-0068), Cerrito, Lucia, Guidi, Luisa, Vecchio, Fabio Maria, Miele, Luca, Guidi, Luisa (ORCID:0000-0003-3320-7094), Vecchio, Fabio M (ORCID:0000-0002-9197-2264), and Miele, Luca (ORCID:0000-0003-3464-0068)

Abstract

N/A

Published
2023

6. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

Author

Leone, Salvatore, Previtali, Enrica, Aloi, Marina, Alvisi, Patrizia, Antonelli, Elisabetta, Ardizzone, Sandro, Astegiano, Marco, Baldoni, Monia, Beltrami, Marina, Biancone, Livia, Bodini, Giorgia, Buda, Andrea, Bossa, Fabrizio, Bracci, Fiammetta, Calabrese, Emma, Cappello, Maria, Castiglione, Fabiana, Ciacci, Carolina, Cicala, Michele, Ciccocioppo, Rachele, Comberlato, Michele, Cortelezzi, Claudio Camillo, Cosintino, Rocco, Costa, Francesco, Costantino, Giuseppe, Cucchiara, Salvatore, Cuomo, Antonio, D’Incà, Renata, Di Paolo, Maria Carla, Di Sabatino, Antonio, Di Sario, Antonio, Frieri, Giuseppe, Fries, Walter, Gasbarrini, Antonio, Geccherle, Andrea, Gionchetti, Paolo, Graziani, Maria Giovanna, Grossi, Laurino, Guidi, Luisa, Imperiali, Gianni, Latella, Giovanni, Lionetti, Paolo, Inserra, Gaetano, Maconi, Giovanni, Manguso, Francesco, Marino, Marco, Mastronardi, Mauro, Mazzuoli, Silvia, Meucci, Gianmichele, Mendolaro, Marco, Milla, Monica, Mocci, Giammarco, Monteleone, Giovanni, Bortoluzzi, Francesco Neri, Pagnini, Cristiano, Pastorelli, Luca, Pica, Roberta, Piergallini, Simona, Privitera, Antonello, Renna, Sara, Ribaldone, Davide Giuseppe, Ricci, Chiara, Rispo, Antonio, Rocca, Rodolfo, Romano, Claudio, Romano, Marco, Russo, Giovanni, Sablich, Renato, Saibeni, Simone, Savarino, Edoardo, Scribano, Maria Lia, Spagnuolo, Rocco, Stasi, Elisa, Terpin, Maria Maddalena, Testa, Anna, Valpiani, Daniela, Variola, Angela, Vernia, Piero, Vitale, Giovanna, Zoli, Giorgio, Fiorino, Gionata, Caprioli, Flavio, Daperno, Marco, Mocciaro, Filippo, Principi, Mariabeatrice, Viscido, Angelo, Fantini, Massimo Claudio, Orlando, Ambrogio, Papi, Claudio, Annese, Vito, Danese, Silvio, Vecchi, Maurizio, Rizzello, Fernando, and Armuzzi, Alessandro

Published
2019
Full Text
View/download PDF

8. Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies

Author

Huinink, S ten Bokkel, primary, Thomassen, Doranne, additional, Steyerberg, Ewout W, additional, Pauwels, Renske W M, additional, Casanova, Maria J, additional, Bouguen, Guillaume, additional, Mak, Joyce W Y, additional, Molnár, Tamas, additional, Lobo, Alan J, additional, Seidelin, Jacob B, additional, Amiot, Aurelien, additional, D’Haens, Geert, additional, Rivière, Pauline, additional, Guidi, Luisa, additional, Bor, Renata, additional, Lin, Wei-Chen, additional, Peyrin-Biroulet, Laurent, additional, Gisbert, Javier P, additional, van der Woude, C Janneke, additional, and de Vries, Annemarie C, additional

Published
2023
Full Text
View/download PDF

9. Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study

Author

Daperno, Marco, Bortoli, Aurora, Kohn, Anna, Politi, Patrizia, Marconi, Stefano, Ardizzone, Sandro, Cortelezzi, Claudio Camillo, Grasso, Gianalberto, Ferraris, Luca, Milla, Monica, Spina, Luisa, Guidi, Luisa, Losco, Alessandra, Inserra, Gaetano, Sablich, Renato, Morganti, Daniela, Bodini, Giorgia, and Comberlato, Michele

Published
2017
Full Text
View/download PDF

10. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

Author

Aratari, Annalisa, Bossa, Fabrizio, Cappello, Maria, Cassinotti, Andrea, Chiriatti, Alberto, Fiorino, Gionata, Formica, Vincenzo, Guidi, Luisa, Losco, Alessandra, Mocciaro, Filippo, Onali, Sara, Pastorelli, Luca, Pica, Roberta, Principi, Mariabeatrice, Renna, Sara, Ricci, Chiara, Rispo, Antonio, Rogai, Francesca, Sarmati, Loredana, Scaldaferri, Franco, Spina, Luisa, Tambasco, Rosy, Testa, Anna, Viscido, Angelo, Biancone, Livia, Annese, Vito, Ardizzone, Sandro, Armuzzi, Alessandro, Calabrese, Emma, Caprioli, Flavio, Castiglione, Fabiana, Comberlato, Michele, Cottone, Mario, Danese, Silvio, Daperno, Marco, D’Incà, Renata, Frieri, Giuseppe, Fries, Walter, Gionchetti, Paolo, Kohn, Anna, Latella, Giovanni, Milla, Monica, Orlando, Ambrogio, Papi, Claudio, Petruzziello, Carmelina, Riegler, Gabriele, Rizzello, Fernando, Saibeni, Simone, Scribano, Maria Lia, Vecchi, Maurizio, Vernia, Piero, and Meucci, Gianmichele

Published
2017
Full Text
View/download PDF

11. Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies.

Author

Huinink, Sebastiaan ten Bokkel, Thomassen, Doranne, Steyerberg, Ewout W, Pauwels, Renske W M, Casanova, Maria J, Bouguen, Guillaume, Mak, Joyce W Y, Molnár, Tamas, Lobo, Alan J, Seidelin, Jacob B, Amiot, Aurelien, D'Haens, Geert, Rivière, Pauline, Guidi, Luisa, Bor, Renata, Lin, Wei-Chen, Peyrin-Biroulet, Laurent, Gisbert, Javier P, Woude, C Janneke van der, and Vries, Annemarie C de

Abstract

Background The risk of relapse after anti-tumour necrosis factor [TNF] therapy discontinuation in Crohn's disease patients with perianal fistulas [pCD] is unclear. We aimed to assess this risk. Methods A systematic literature search was conducted to identify cohort studies on the incidence of relapse following anti-TNF discontinuation in pCD patients. Individual participant data were requested from the original study cohorts. Inclusion criteria were age ≥16 years, pCD as a (co)indication for start of anti-TNF therapy, more than three doses, and remission of luminal and pCD at anti-TNF discontinuation. The primary outcome was the cumulative incidence of CD relapse using Kaplan–Meier estimates. Secondary outcomes included response to re-treatment and risk factors associated with relapse as assessed by Cox regression analysis. Results In total, 309 patients from 12 studies in ten countries were included. The median duration of anti-TNF treatment was 14 months [interquartile range 5.8–32.5]. Most patients were treated for pCD without active luminal disease [89%], received first-line anti-TNF therapy [87%], and continued immunomodulatory therapy following anti-TNF discontinuation [78%]. The overall cumulative incidence of relapse was 36% (95% confidence interval [CI] 25–48%) and 42% [95% CI 32–53%] at 1 and 2 years after anti-TNF discontinuation, respectively. Risk factors for relapse included smoking (hazard ratio [HR] 1.5 [1.0, 2.1]) and history of proctitis (HR 1.7 [1.1, 2.5]). The overall re-treatment response rate was 82%. Conclusions This individual participant data meta-analysis, on predominantly patients with pCD without active luminal disease and first-line anti-TNF therapy, shows that over half of patients remain in remission 2 years after anti-TNF discontinuation. Therefore, anti-TNF discontinuation may be considered in this subgroup. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

Author

Armuzzi, Alessandro, Fiorino, Gionata, Variola, Angela, Manetti, Natalia, Fries, Walter, Orlando, Ambrogio, Maconi, Giovanni, Bossa, Fabrizio, Cappello, Maria, Biancone, Livia, Cantoro, Laura, Costa, Francesco, D’Incà, Renata, Lionetti, Paolo, Principi, Mariabeatrice, Castiglione, Fabiana, Annunziata, Maria L, Di Sabatino, Antonio, Di Girolamo, Maria, Terpin, Maria M, Cortelezzi, Claudio C, Saibeni, Simone, Amato, Arnaldo, Ardizzone, Sandro, Guidi, Luisa, Danese, Silvio, Massella, Arianna, Ventra, Agostino, Rizzuto, Giulia, Massari, Alessandro, Perri, Francesco, Annese, Vito, Saettone, Silvia, Tari, Roberto, Petruzzellis, Carlo, Meucci, Gianmichele, Imperiali, Gianni, Guglielmi, Francesco W, Mazzuoli, Silvia, Caserta, Luigi, Caterina Parodi, Maria, Colli, Agostino, Ronchetti, Anna, Pugliese, Daniela, Geccherle, Andrea, Rogai, Francesca, Milani, Stefano, Renna, Sara, Cassinotti, Andrea, Andriulli, Angelo, Martino, Giuseppina, Scrivo, Barbara, Troncone, Edoardo, Kohn, Anna, Bertani, Lorenzo, Lorenzon, Greta, Ghione, Silvia, Nardone, Olga, Vecchi, Maurizio, Bertani, Angela, Bosani, Matteo A, Bezzio, Cristina, and Salerno, Raffaele

Published
2019
Full Text
View/download PDF

14. Watery stools and metabolic acidosis

Author

Ferrari, Maria Chiara, Miele, Luca, Guidi, Luisa, Rindi, Guido, Rocchi, Carlo, Castaldi, Paola, Alfieri, Sergio, Gasbarrini, Antonio, Grieco, Antonio, and Rapaccini, Gianlodovico

Published
2017
Full Text
View/download PDF

17. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

Author

Monterubbianesi, Rita, Aratari, Annalisa, Armuzzi, Alessandro, Daperno, Marco, Biancone, Livia, Cappello, Maria, Annese, Vito, Riegler, Gabriele, Orlando, Ambrogio, Viscido, Angelo, Meucci, Gianmichele, Gasbarrini, Antonio, Guidi, Luisa, Lavagna, Alessandro, Sostegni, Raffaello, Onali, Sara, Papi, Claudio, and Kohn, Anna

Published
2014
Full Text
View/download PDF

20. Adalimumab in active ulcerative colitis: A “real-life” observational study

Author

Armuzzi, Alessandro, Biancone, Livia, Daperno, Marco, Coli, Alessandra, Pugliese, Daniela, Annese, Vito, Aratari, Annalisa, Ardizzone, Sandro, Balestrieri, Paola, Bossa, Fabrizio, Cappello, Maria, Castiglione, Fabiana, Cicala, Michele, Danese, Silvio, D’Incà, Renata, Dulbecco, Pietro, Feliciangeli, Giuseppe, Fries, Walter, Genise, Stefania, Gionchetti, Paolo, Gozzi, Stefano, Kohn, Anna, Lorenzetti, Roberto, Milla, Monica, Onali, Sara, Orlando, Ambrogio, Papparella, Luigi Giovanni, Renna, Sara, Ricci, Chiara, Rizzello, Fernando, Sostegni, Raffaello, Guidi, Luisa, and Papi, Claudio

Published
2013
Full Text
View/download PDF

21. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease

Author

Privitera, Giuseppe, Onali, Sara, Pugliese, Daniela, Renna, Sara, Savarino, Edoardo, Viola, Antonella Anna Paola, Ribaldone, Davide Giuseppe, Buda, Andrea, Bezzio, Cristina, Fiorino, Gionata, Fantini, Massimo Claudio, Scaldaferri, Franco, Guidi, Luisa, Danese, Silvio, Gasbarrini, Antonio, Orlando, Ambrogio, Armuzzi, Alessandro, Viola, Anna, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Guidi, Luisa (ORCID:0000-0003-3320-7094), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Privitera, Giuseppe, Onali, Sara, Pugliese, Daniela, Renna, Sara, Savarino, Edoardo, Viola, Antonella Anna Paola, Ribaldone, Davide Giuseppe, Buda, Andrea, Bezzio, Cristina, Fiorino, Gionata, Fantini, Massimo Claudio, Scaldaferri, Franco, Guidi, Luisa, Danese, Silvio, Gasbarrini, Antonio, Orlando, Ambrogio, Armuzzi, Alessandro, Viola, Anna, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Guidi, Luisa (ORCID:0000-0003-3320-7094), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Armuzzi, Alessandro (ORCID:0000-0003-1572-0118)

Abstract

N/A

Published
2020

23. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar

Author

Fiorino, Gionata, Manetti, Natalia, Armuzzi, Alessandro, Orlando, Ambrogio, Variola, Angela, Bonovas, Stefanos, Bossa, Fabrizio, Maconi, Giovanni, DʼIncà, Renata, Lionetti, Paolo, Cantoro, Laura, Fries, Walter, Annunziata, Maria L., Costa, Francesco, Terpin, Maria M., Biancone, Livia, Cortelezzi, Claudio C., Amato, Arnaldo, Ardizzone, Sandro, Danese, Silvio, Guidi, Luisa, Rizzuto, Giulia, Massella, Arianna, Andriulli, Angelo, Massari, Alessandro, Lorenzon, Greta, Ghione, Silvia, Kohn, Anna, Ventra, Agostino, and Annese, Vito

Published
2017
Full Text
View/download PDF

24. Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease

Author

Cottone, Mario, Kohn, Anna, Daperno, Marco, Armuzzi, Alessandro, Guidi, Luisa, D'Inca, Renata, Bossa, Fabrizio, Angelucci, Erika, Biancone, Livia, Gionchetti, Paolo, Ardizzone, Sandro, Papi, Claudio, Fries, Walter, Danese, Silvio, Riegler, Gabriele, Cappello, Maria, Castiglione, Fabiana, Annese, Vito, and Orlando, Ambrogio

Published
2011
Full Text
View/download PDF

25. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy

Author

Tursi, Antonio, primary, Mocci, Giammarco, additional, Allegretta, Leonardo, additional, Aragona, Giovanni, additional, Bianco, Maria Antonia, additional, Colucci, Raffaele, additional, Cuomo, Antonio, additional, Della Valle, Nicola, additional, Ferronato, Antonio, additional, Forti, Giacomo, additional, Gaiani, Federica, additional, Graziani, Maria Giovanna, additional, Lorenzetti, Roberto, additional, Luzza, Francesco, additional, Paese, Pietro, additional, Penna, Antonio, additional, Pica, Roberta, additional, Pranzo, Giuseppe, additional, Rodinò, Stefano, additional, Scarcelli, Antonella, additional, Zampaletta, Costantino, additional, Brozzi, Lorenzo, additional, Cicerone, Clelia, additional, Cocco, Andrea, additional, De’ Angelis, Gianluigi, additional, Donnarumma, Laura, additional, Fiorella, Serafina, additional, Iannelli, Chiara, additional, Larussa, Tiziana, additional, Le Grazie, Marco, additional, Luppino, Ileana, additional, Meucci, Costantino, additional, FaggianI, Roberto, additional, Pagnini, Cristiano, additional, Perazzo, Patrizia, additional, Rodriguez-Castro, Kryssia Isabel, additional, Sacco, Rodolfo, additional, Sebkova, Ladislava, additional, Serio, Mariaelena, additional, De Monti, Alberta, additional, Picchio, Marcello, additional, Napolitano, Daniele, additional, Schiavoni, Elisa, additional, Turchini, Laura, additional, Scaldaferri, Franco, additional, Pugliese, Daniela, additional, Guidi, Luisa, additional, Laterza, Lucrezia, additional, Privitera, Giuseppe, additional, Pizzoferrato, Marco, additional, Lopetuso, Loris R., additional, Armuzzi, Alessandro, additional, Elisei, Walter, additional, Maconi, Giovanni, additional, and Papa, Alfredo, additional

Published
2021
Full Text
View/download PDF

26. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Author

Guidi, Luisa, Pugliese, Daniela, Tonucci, Tommaso Panici, Bertani, Lorenzo, Costa, Francesco, Privitera, Giuseppe, Tolusso, Barbara, Di Mario, Clara, Albano, Eleonora, Tapete, Gherardo, Gremese, Elisa, Papa, Alfredo, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Armuzzi, Alessandro, Guidi, Luisa (ORCID:0000-0003-3320-7094), Tolusso, Barbara (ORCID:0000-0002-9108-6609), Gremese, Elisa (ORCID:0000-0002-2248-1058), Papa, Alfredo (ORCID:0000-0002-4186-7298), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Guidi, Luisa, Pugliese, Daniela, Tonucci, Tommaso Panici, Bertani, Lorenzo, Costa, Francesco, Privitera, Giuseppe, Tolusso, Barbara, Di Mario, Clara, Albano, Eleonora, Tapete, Gherardo, Gremese, Elisa, Papa, Alfredo, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Armuzzi, Alessandro, Guidi, Luisa (ORCID:0000-0003-3320-7094), Tolusso, Barbara (ORCID:0000-0002-9108-6609), Gremese, Elisa (ORCID:0000-0002-2248-1058), Papa, Alfredo (ORCID:0000-0002-4186-7298), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), and Armuzzi, Alessandro (ORCID:0000-0003-1572-0118)

Abstract

BACKGROUND: Data from trials of vedolizumab for inflammatory bowel disease and from real-world studies suggest an exposure-response relationship, such that vedolizumab trough levels may predict clinical and endoscopic outcomes. OBJECTIVE: The purpose of this study was to evaluate in a prospective observational study the utility of an early vedolizumab trough level assay for predicting the first-year vedolizumab therapy outcome. METHODS: This prospective observational study included consecutive inflammatory bowel disease patients. We measured vedolizumab trough levels and anti-vedolizumab antibodies at weeks 6 and 14. Clinical outcome was assessed at weeks 6, 14, 22 and 54. The primary endpoint was the correlation between early vedolizumab trough levels and vedolizumab persistence over the first year of treatment, defined as the maintenance of vedolizumab therapy due to sustained clinical benefit. RESULTS: We included 101 patients initiating vedolizumab. A cut-off vedolizumab trough level of 16.55 µg/ml at week 14 predicted vedolizumab persistence within the first year of therapy, with 73.3% sensitivity and 59.4% specificity (p = 0.0009). Week 14 vedolizumab trough level was significantly higher in patients with clinical remission at weeks 14, 22 and 54; and in patients achieving mucosal healing within 54 weeks. CONCLUSION: High vedolizumab trough level at week 14 was associated with a higher probability of maintaining vedolizumab therapy over the first year due to sustained clinical benefit.

Published
2019

27. Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease

Author

Pugliese, Daniela, Privitera, Giuseppe, Pizzolante, Fabrizio, Gasbarrini, Antonio, Guidi, Luisa, Armuzzi, Alessandro, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Guidi, Luisa (ORCID:0000-0003-3320-7094), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Pugliese, Daniela, Privitera, Giuseppe, Pizzolante, Fabrizio, Gasbarrini, Antonio, Guidi, Luisa, Armuzzi, Alessandro, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Guidi, Luisa (ORCID:0000-0003-3320-7094), and Armuzzi, Alessandro (ORCID:0000-0003-1572-0118)

Abstract

N/A

Published
2019

28. Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period

Author

Scaldaferri, Franco, Papa, Alfredo, Napolitano, Daniele, Rizzatti, Gianenrico, Pistone, M. T., Poscia, Andrea, Volpe, Massimo, Lopetuso, Loris Riccardo, Schiavoni, Elisa, Guidi, Luisa, Gaetani, Eleonora, Holleran, G., Cammarota, Giovanni, Rapaccini, Gian Ludovico, Pugliese, Daniela, Ojetti, Veronica, Franceschi, Francesco, Armuzzi, Alessandro, and Gasbarrini, Antonio

Subjects
Hospitalizations, Settore MED/12 - GASTROENTEROLOGIA, Healthcare organization, Inflammatory bowel disease, Biologic therapy
Published
2021

29. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients

Author

Pugliese, Daniela, Guidi, Luisa, Privitera, Giuseppe, Bertani, L., Tolusso, Barbara, Papparella, Luigi Giovanni, Maltinti, S., Di Mario, Clara, Onali, Sebastiano, Ceccarelli, L., Rapaccini, Gian Ludovico, Scaldaferri, Franco, Gremese, Elisa, Gasbarrini, Antonio, Costa, F., Armuzzi, Alessandro, Pugliese D., Guidi L. (ORCID:0000-0003-3320-7094), Privitera G., Tolusso B. (ORCID:0000-0002-9108-6609), Papparella L. G., Di Mario C., Onali S., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Scaldaferri F. (ORCID:0000-0001-8334-7541), Gremese E. (ORCID:0000-0002-2248-1058), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Pugliese, Daniela, Guidi, Luisa, Privitera, Giuseppe, Bertani, L., Tolusso, Barbara, Papparella, Luigi Giovanni, Maltinti, S., Di Mario, Clara, Onali, Sebastiano, Ceccarelli, L., Rapaccini, Gian Ludovico, Scaldaferri, Franco, Gremese, Elisa, Gasbarrini, Antonio, Costa, F., Armuzzi, Alessandro, Pugliese D., Guidi L. (ORCID:0000-0003-3320-7094), Privitera G., Tolusso B. (ORCID:0000-0002-9108-6609), Papparella L. G., Di Mario C., Onali S., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Scaldaferri F. (ORCID:0000-0001-8334-7541), Gremese E. (ORCID:0000-0002-2248-1058), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Armuzzi A. (ORCID:0000-0003-1572-0118)

Abstract

Background: Switching from IFX originator to CT-P13 is safe; however, little data on immunogenicity exists. Research design and methods: Consecutive IBD patients on IFX originator were switched to CT-P13 and followed-up for 12 months. Clinical activity, infliximab trough levels (ITLs), anti-drug antibodies (ATIs), and adverse events were recorded at predefined timepoints (baseline, second CT-P13 infusion, 6 and 12 months). The outcomes investigated were immunogenicity, pharmacokinetics, effectiveness and safety. Results: 119 patients were switched to CT-P13 after a median time with IFX of 5.8 years. No changes in mean ITLs were observed. ATIs were detected in 30 patients (25.2%): 14 before and 16 after switch. Mean persistent ATIs were significantly higher compared to mean transient ones (109.74 ng/mL ±84.70 vs 18.22 ng/mL ±11.37, p < 0.001), with significantly lower ITLs associated (mean 0.32 µg/mL ±0.6 vs 3.08 µg/mL ±3.22, p < 0.001). A significant decrease of patients in steroid-fee clinical remission was observed after the switch (p = 0.004), with subsequent improvement at 6 months (p = 0.005). Eighteen patients (15.1%) discontinued IFX, only 6 (5%) for loss of response. Conclusions: Switching from infliximab originator to CT-P13 seems safe and effective, without differences in immunogenicity. A temporary reduction of clinical benefit after switching could be potentially explained by a ‘nocebo-effect response’.

Published
2021

30. Predictors and early markers of response to biological therapies in inflammatory bowel diseases

Author

Privitera, Giuseppe, Pugliese, Daniela, Rapaccini, Gian Ludovico, Gasbarrini, Antonio, Armuzzi, Alessandro, Guidi, Luisa, Privitera G., Pugliese D., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Guidi L. (ORCID:0000-0003-3320-7094), Privitera, Giuseppe, Pugliese, Daniela, Rapaccini, Gian Ludovico, Gasbarrini, Antonio, Armuzzi, Alessandro, Guidi, Luisa, Privitera G., Pugliese D., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), and Guidi L. (ORCID:0000-0003-3320-7094)

Abstract

Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gas-trointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogene-ity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immuno-logical, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.

Published
2021

31. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches

Author

Privitera, Giuseppe, Pugliese, Daniela, Lopetuso, Loris Riccardo, Scaldaferri, Franco, Neri, Maria Luisa, Guidi, Luisa, Gasbarrini, Antonio, Armuzzi, Alessandro, Privitera G., Pugliese D., Lopetuso L. R., Scaldaferri F. (ORCID:0000-0001-8334-7541), Neri M., Guidi L. (ORCID:0000-0003-3320-7094), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Privitera, Giuseppe, Pugliese, Daniela, Lopetuso, Loris Riccardo, Scaldaferri, Franco, Neri, Maria Luisa, Guidi, Luisa, Gasbarrini, Antonio, Armuzzi, Alessandro, Privitera G., Pugliese D., Lopetuso L. R., Scaldaferri F. (ORCID:0000-0001-8334-7541), Neri M., Guidi L. (ORCID:0000-0003-3320-7094), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Armuzzi A. (ORCID:0000-0003-1572-0118)

Abstract

Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the extent of their efficacy might be, at least partially, dependent on the timing of their introduction and on the subsequent management strategy. In this complex landscape, the potential role for a more dynamic approach with treatments based on sequencing and combining targeted therapies has been explored only minimally so far. In this review, we aim to explore the potential biological rationale behind the use of sequential and combination therapies in IBD, to summarise the current knowledge on this topic and to propose a management algorithm that combines these notions.

Published
2021

32. Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach

Author

Corsello, Andrea, Pugliese, Daniela, Bracci, Francesca, Knafelz, D., Papadatou, B., Aloi, M., Cucchiara, S., Guidi, Luisa, Gasbarrini, Antonio, Armuzzi, Alessandro, Corsello A., Pugliese D., Bracci F., Guidi L. (ORCID:0000-0003-3320-7094), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Corsello, Andrea, Pugliese, Daniela, Bracci, Francesca, Knafelz, D., Papadatou, B., Aloi, M., Cucchiara, S., Guidi, Luisa, Gasbarrini, Antonio, Armuzzi, Alessandro, Corsello A., Pugliese D., Bracci F., Guidi L. (ORCID:0000-0003-3320-7094), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Armuzzi A. (ORCID:0000-0003-1572-0118)

Abstract

Background: Transition from pediatric to adult care of patients affected by Inflammatory Bowel Disease (IBD) is a critical step that needs specific care and multidisciplinary involvement. The aim of our study was to evaluate the outcome of the transition process of a cohort of IBD patients, exploring their readiness and the possible impact on quality of life. Methods: This observational study followed transitioned IBD patients from pediatric to adult care. Transition was carried-out through combined visits, jointly performed by the pediatrician and the adult gastroenterologist. Clinical data were collected before and after transition. A subgroup of patients was submitted to an anonymous online questionnaire of 38 items based on the validated questionnaires TRAQ and SIBDQ within the first 6 months from the beginning of the transition process. Results: Eighty-two patients with IBD were enrolled, with a mean age at transition of 20.2±2.7 years. Before transition, 40.2% of patients already had major surgery and 64.6% started biologics. At transition, 24% of patients were in moderate to severe active phase of their disease and 40% of them had already been treated with ≥ 2 biologics. The mean score of the TRAQ questionnaires collected is 3.4±1.5 and the mean score of SIBDQ is 53.9±9.8. A significant association was found between a TRAQ mean score > 3 and a SIBDQ > 50 (p=0.0129). Overall, 75% of patients had a positive opinion of the transition model adopted. Conclusions: A strong association has been found between TRAQ and SIBDQ questionnaires, showing how transition readiness has a direct impact on the quality of life of the young adult with IBD.

Published
2021

36. Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study.

Author

Guidi, Luisa, Pugliese, Daniela, Panici Tonucci, Tommaso, Berrino, Alexandra Maura, Tolusso, Barbara, Basile, Michele, Cantoro, Laura, Balestrieri, Paola, Civitelli, Fortunata, Bertani, Lorenzo, Marzo, Manuela, Felice, Carla, Gremese, Elisa, Costa, Francesco, Viola, Franca, Cicala, Michele, Kohn, Anna, Gasbarrini, Antonio, Rapaccini, Gian Lodovico, Ruggeri, Matteo, Armuzzi, Alessandro, Guidi, Luisa (ORCID:0000-0003-3320-7094), Tolusso, Barbara (ORCID:0000-0002-9108-6609), Gremese, Elisa (ORCID:0000-0002-2248-1058), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Ruggeri, Matteo (ORCID:0000-0002-5703-7424), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Guidi, Luisa, Pugliese, Daniela, Panici Tonucci, Tommaso, Berrino, Alexandra Maura, Tolusso, Barbara, Basile, Michele, Cantoro, Laura, Balestrieri, Paola, Civitelli, Fortunata, Bertani, Lorenzo, Marzo, Manuela, Felice, Carla, Gremese, Elisa, Costa, Francesco, Viola, Franca, Cicala, Michele, Kohn, Anna, Gasbarrini, Antonio, Rapaccini, Gian Lodovico, Ruggeri, Matteo, Armuzzi, Alessandro, Guidi, Luisa (ORCID:0000-0003-3320-7094), Tolusso, Barbara (ORCID:0000-0002-9108-6609), Gremese, Elisa (ORCID:0000-0002-2248-1058), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Ruggeri, Matteo (ORCID:0000-0002-5703-7424), and Armuzzi, Alessandro (ORCID:0000-0003-1572-0118)

Abstract

BACKGROUND: Empirical dose intensification and therapeutic drug monitoring (TDM) of infliximab (IFX) trough levels (ITL) and antibody (ATI) assays are recognised approaches for managing the loss of response (LoR) in inflammatory bowel disease (IBD) patients. AIM: To compare these two interventions in a clinical setting, in terms of effectiveness and cost savings. METHODS: Consecutive IBD patients, experiencing LoR, were clinically managed according to a TDM algorithm. A historical group of empirically treated patients, for whom sera for ITL and ATI assays were collected, served as the control group. Clinical outcomes 12 weeks after the therapeutic interventions were compared between the two groups. A cost-minimization analysis was performed to compare the economic impact of these two approaches. RESULTS: Ninety-six patients were enrolled prospectively and compared with 52 controls. The two cohorts were similar in characteristics and the distribution of TDM results. In the prospective cohort, however, we observed less IFX dose escalations compared with controls (45% versus 71%, p=0.003). Also, more patients were switched to a different anti-TNF in the prospective cohort than in the control one (25% versus 4%, p=0.001). The percentages of patients achieving a clinical response at 12 weeks were 52% and 54% for the prospective and control groups, respectively. By cost analysis, we estimated a savings of 15% if the TDM algorithm was applied. CONCLUSIONS: In our population, applying a TDM algorithm for LoR to IFX resulted in less dose escalations, without loss of efficacy, compared with empirical adjustment. In addition, the TDM approach was cost-effective.

Published
2018

38. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Author

Scaldaferri, Franco, Pugliese, Daniela, Privitera, Giuseppe, Onali, Sebastiano, Lopetuso, Loris Riccardo, Rizzatti, Gianenrico, Settanni, Carlo Romano, Pizzoferrato, Marco, Schiavoni, Elisa, Turchini, Laura, Amatucci, V., Napolitano, Daniele, Bernabei, T., Mora, Vincenzina, Laterza, Lucrezia, Papa, Alfredo, Guidi, Luisa, Rapaccini, Gian Ludovico, Gasbarrini, Antonio, Armuzzi, Alessandro, Scaldaferri F. (ORCID:0000-0001-8334-7541), Pugliese D., Privitera G., Onali S., Lopetuso L. R., Rizzatti G. (ORCID:0000-0003-1876-7587), Settanni C. R., Pizzoferrato M., Schiavoni E., Turchini L., Napolitano D., Mora V., Laterza L., Papa A. (ORCID:0000-0002-4186-7298), Guidi L. (ORCID:0000-0003-3320-7094), Rapaccini G. L. (ORCID:0000-0002-6467-857X), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Scaldaferri, Franco, Pugliese, Daniela, Privitera, Giuseppe, Onali, Sebastiano, Lopetuso, Loris Riccardo, Rizzatti, Gianenrico, Settanni, Carlo Romano, Pizzoferrato, Marco, Schiavoni, Elisa, Turchini, Laura, Amatucci, V., Napolitano, Daniele, Bernabei, T., Mora, Vincenzina, Laterza, Lucrezia, Papa, Alfredo, Guidi, Luisa, Rapaccini, Gian Ludovico, Gasbarrini, Antonio, Armuzzi, Alessandro, Scaldaferri F. (ORCID:0000-0001-8334-7541), Pugliese D., Privitera G., Onali S., Lopetuso L. R., Rizzatti G. (ORCID:0000-0003-1876-7587), Settanni C. R., Pizzoferrato M., Schiavoni E., Turchini L., Napolitano D., Mora V., Laterza L., Papa A. (ORCID:0000-0002-4186-7298), Guidi L. (ORCID:0000-0003-3320-7094), Rapaccini G. L. (ORCID:0000-0002-6467-857X), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Armuzzi A. (ORCID:0000-0003-1572-0118)

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is having a major clinical as well as organisational impact on the national health-care system in Italy, particularly in high-volume hospitals which are usually active for many essential clinical needs, including inflammatory bowel disease (IBD). Here, we report major clinical and organisational challenges at a high-volume Italian IBD centre one month after the start of the Italian government’s restrictions due to the COVID-19 pandemic. All routine follow-up IBD visits of patients in remission were cancelled or rescheduled for 8–12 weeks’ time. However, access to the hospital for therapy or for unstable/relapsing patients was not considered postponable. Everyone attending the centre (e.g. physicians, nurses, administrative personnel and patients) were advised to respect the general recommended rules for hand hygiene and social distancing, to disclose if they had a fever or cough or flu-like symptoms and to wear a surgical mask and gloves. At the entrance of the therapy area, a control station was set up in order to double-check all patients with a clinical interview and conduct thermal scanning. A total of 1451 IBD patients under biotechnological or experimental therapy actively followed in the CEMAD IBD centre were included in the study. About 65% of patients maintained their appointment schedules without major problems, while in 20% of cases planned infusions were delayed because of the patient’s decision or practical issues. About 10% of patients receiving subcutaneous therapy were allowed to collect their medicine without a follow-up visit. Finally, 10% of patients living outside the Lazio region requested access to their therapy at a local centre closer to their home. At present, five patients have been found to be positive for SARS-CoV-2 infection but with minimal symptoms, 22 are in ‘quarantine’ for contact considered to be ‘at risk’ for the infection. Up to now, none of them has experienced significant symptom

Published
2020

39. Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy

Author

Pietropaolo, G., Pugliese, Daniela, Armuzzi, Alessandro, Guidi, Luisa, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Wolf Minotti, Federica, Trapani, Valentina, Pugliese, D., Armuzzi A. (ORCID:0000-0003-1572-0118), Guidi, L. (ORCID:0000-0003-3320-7094), Gasbarrini, A. (ORCID:0000-0002-7278-4823), Rapaccini, G. L. (ORCID:0000-0002-6467-857X), Wolf, F. (ORCID:0000-0003-1361-1049), Trapani, V. (ORCID:0000-0002-0259-6624), Pietropaolo, G., Pugliese, Daniela, Armuzzi, Alessandro, Guidi, Luisa, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Wolf Minotti, Federica, Trapani, Valentina, Pugliese, D., Armuzzi A. (ORCID:0000-0003-1572-0118), Guidi, L. (ORCID:0000-0003-3320-7094), Gasbarrini, A. (ORCID:0000-0002-7278-4823), Rapaccini, G. L. (ORCID:0000-0002-6467-857X), Wolf, F. (ORCID:0000-0003-1361-1049), and Trapani, V. (ORCID:0000-0002-0259-6624)

Abstract

Hypomagnesemia is very commonly observed in cancer patients, most frequently in association with therapy with cetuximab (CTX), a monoclonal antibody targeting the epithelial growth factor receptor (EGFR). CTX-induced hypomagnesemia has been ascribed to renal magnesium (Mg) wasting. Here, we sought to clarify whether CTX may also influence intestinal Mg absorption and if Mg supplementation may interfere with CTX activity. We used human colon carcinoma CaCo-2 cells as an in vitro model to study the mechanisms underlying Mg transport and CTX activity. Our findings demonstrate that TRPM6 is the key channel that mediates Mg influx in intestinal cells and that EGF stimulates such influx; consequently, CTX downregulates TRPM6-mediated Mg influx by interfering with EGF signaling. Moreover, we show that Mg supplementation does not modify either the CTX IC50 or CTX-dependent inhibition of ERK1/2 phosphorylation. Our results suggest that reduced Mg absorption in the intestine may contribute to the severe hypomagnesemia that occurs in CTX-treated patients, and Mg supplementation may represent a safe and effective nutritional intervention to restore Mg status without impairing the CTX efficacy.

Published
2020

40. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study

Author

Biancone, L., Armuzzi, Alessandro, Scribano, M. L., Castiglione, F., D'Inca, R., Orlando, A., Papi, C., Daperno, M., Vecchi, M., Riegler, G., Fries, W., Alvisi, P., Meucci, G., Mocciaro, F., Rogai, F., Festa, S., Guidi, Luisa, Testa, A., Spina, L., Renna, S., Viola, A., Patturelli, M., Di Mitri, R., Frankovic, I., Calabrese, E., Petruzziello, C., De Cristofaro, E., Sena, G., Ruffa, A., Neri, B., Rossi, A., Armuzzi A. (ORCID:0000-0003-1572-0118), Guidi L. (ORCID:0000-0003-3320-7094), Biancone, L., Armuzzi, Alessandro, Scribano, M. L., Castiglione, F., D'Inca, R., Orlando, A., Papi, C., Daperno, M., Vecchi, M., Riegler, G., Fries, W., Alvisi, P., Meucci, G., Mocciaro, F., Rogai, F., Festa, S., Guidi, Luisa, Testa, A., Spina, L., Renna, S., Viola, A., Patturelli, M., Di Mitri, R., Frankovic, I., Calabrese, E., Petruzziello, C., De Cristofaro, E., Sena, G., Ruffa, A., Neri, B., Rossi, A., Armuzzi A. (ORCID:0000-0003-1572-0118), and Guidi L. (ORCID:0000-0003-3320-7094)

Abstract

Background: In a 6-year, multicenter, prospective nested case-control study, we aimed to evaluate risk factors for incident cancer in inflammatory bowel disease (IBD), when considering clinical characteristics of IBD and immunomodulator use. The secondary end point was to provide characterization of incident cancer types. Methods: All incident cases of cancer occurring in IBD patients from December 2011-2017 were prospectively recorded in 16 Italian Group for the Study of Inflammatory Bowel Disease units. Each of the IBD patients with a new diagnosis of cancer was matched with 2 IBD patients without cancer, according to IBD phenotype (ulcerative colitis [UC] vs Crohn's disease [CD]), age (±5 years), sex. Risk factors were assessed by multivariate logistic regression analysis. Results: Cancer occurred in 403 IBD patients: 204 CD (CD cases), 199 UC (UC cases). The study population included 1209 patients (403 IBD cases, 806 IBD controls). Cancer (n = 403) more frequently involved the digestive system (DS; 32%), followed by skin (14.9%), urinary tract (9.7%), lung (6.9%), genital tract (6.5%), breast (5.5%), thyroid (1.9%), lymphoma (2.7%, only in CD), adenocarcinoma of the small bowel (SBA; 3.9%, 15 CD, 1 pouch in UC), other cancers (15.9%). Among cancers of the DS, colorectal cancer (CRC) more frequently occurred in UC (29% vs 17%; P < 0.005), whereas SBA more frequently occurred in CD (13% vs 6.3% P = 0.039). In CD, perforating (B3) vs non-stricturing non-perforating (B1) behavior represented the only risk factor for any cancer (odds ratio [OR], 2.33; 95% confidence interval [CI], 1.33-4.11). In CD, risk factors for extracolonic cancer (ECC) were a B3 vs B1 and a stricturing (B2) vs B1 behavior (OR, 2.95; 95% CI, 1.62-5.43; OR, 1.79; 95% CI, 1.09-2.98). In UC, risk factors for ECC and for overall cancer were abdominal surgery for UC (OR, 4.63; 95% CI, 2.62-8.42; OR, 3.34; 95% CI, 1.88-5.92) and extensive vs distal UC (OR, 1.73; 95% CI, 1.10-2.75; OR, 1.99; 95% CI

Published
2020

43. Serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients

Author

Bertani, Lorenzo, primary, Tricò, Domenico, additional, Pugliese, Daniela, additional, Privitera, Giuseppe, additional, Linsalata, Giuseppe, additional, Zanzi, Federico, additional, Gloria Mumolo, Maria, additional, Barberio, Brigida, additional, Monzani, Fabio, additional, Marchi, Santino, additional, Guidi, Luisa, additional, Blandizzi, Corrado, additional, Armuzzi, Alessandro, additional, and Costa, Francesco, additional

Published
2020
Full Text
View/download PDF

45. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients

Author

Pugliese, Daniela, primary, Guidi, Luisa, additional, Privitera, Giuseppe, additional, Bertani, Lorenzo, additional, Tolusso, Barbara, additional, Papparella, Luigi Giovanni, additional, Maltinti, Simona, additional, Di Mario, Clara, additional, Onali, Sara, additional, Ceccarelli, Linda, additional, Rapaccini, Gian Lodovico, additional, Scaldaferri, Franco, additional, Gremese, Elisa, additional, Gasbarrini, Antonio, additional, Costa, Francesco, additional, and Armuzzi, Alessandro, additional

Published
2020
Full Text
View/download PDF

47. Impact of COVID‐19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high‐volume Italian inflammatory bowel disease centre

Author

Scaldaferri, Franco, primary, Pugliese, Daniela, additional, Privitera, Giuseppe, additional, Onali, Sara, additional, Lopetuso, Loris Riccardo, additional, Rizzatti, Gianenrico, additional, Settanni, Carlo Romano, additional, Pizzoferrato, Marco, additional, Schiavoni, Elisa, additional, Turchini, Laura, additional, Amatucci, Valeria, additional, Napolitano, Daniele, additional, Bernabei, Tiziana, additional, Mora, Vincenzina, additional, Laterza, Lucrezia, additional, Papa, Alfredo, additional, Guidi, Luisa, additional, Rapaccini, Gian Lodovico, additional, Gasbarrini, Antonio, additional, and Armuzzi, Alessandro, additional

Published
2020
Full Text
View/download PDF

48. Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease

Author

Privitera, Giuseppe, primary, Onali, Sara, additional, Pugliese, Daniela, additional, Renna, Sara, additional, Savarino, Edoardo, additional, Viola, Anna, additional, Ribaldone, Davide Giuseppe, additional, Buda, Andrea, additional, Bezzio, Cristina, additional, Fiorino, Gionata, additional, Fantini, Massimo Claudio, additional, Scaldaferri, Franco, additional, Guidi, Luisa, additional, Danese, Silvio, additional, Gasbarrini, Antonio, additional, Orlando, Ambrogio, additional, and Armuzzi, Alessandro, additional

Published
2020
Full Text
View/download PDF

49. Mo1867 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Author

Pugliese, Daniela, primary, Privitera, Giuseppe, additional, Crispino, Federica, additional, Mezzina, Nicolò, additional, Pellegrini, Lucienne, additional, Laterza, Lucrezia, additional, Viola, Anna, additional, Soru, Pietro, additional, Scrivo, Barbara, additional, Barberio, Brigida, additional, Ricci, Chiara, additional, pluchino, dario, additional, Scribano, Maria Lia, additional, Bertani, Lorenzo, additional, Sablich, Renato, additional, Pastorelli, Luca, additional, Manguso, Francesco, additional, Variola, Angela, additional, Di Sario, Antonio, additional, Grossi, Laurino, additional, Ribaldone, Davide Giuseppe, additional, Biscaglia, Giuseppe, additional, Buda, Andrea, additional, Balestrieri, Paola, additional, Mocci, Giammarco, additional, Viscido, Angelo, additional, Di Paolo, Maria Carla, additional, Onali, Sara, additional, Rodino', Stefano, additional, Coletta, Marina, additional, Principi, Mariabeatrice, additional, Miranda, Agnese, additional, Amato, Arnaldo, additional, Bezzio, Cristina, additional, Petruzzellis, Carlo, additional, Mazzuoli, Silvia, additional, Festa, Stefano, additional, Sartini, Alessandro, additional, Fanigliulo, Libera, additional, Gallina, Sara, additional, Bodini, Giorgia, additional, Guidi, Luisa, additional, Savarino, Edoardo, additional, Cappello, Maria, additional, Caprioli, Flavio, additional, Fries, Walter, additional, Scaldaferri, Franco, additional, Castiglione, Fabiana, additional, Massari, Alessandro, additional, Orlando, Ambrogio, additional, and Armuzzi, Alessandro, additional

Published
2020
Full Text
View/download PDF

50. Sa1825 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT

Author

Pugliese, Daniela, primary, Privitera, Giuseppe, additional, Crispino, Federica, additional, Mezzina, Nicolò, additional, Pellegrini, Lucienne, additional, Laterza, Lucrezia, additional, Viola, Anna, additional, Soru, Pietro, additional, Scrivo, Barbara, additional, Barberio, Brigida, additional, Ricci, Chiara, additional, pluchino, dario, additional, Scribano, Maria Lia, additional, Bertani, Lorenzo, additional, Sablich, Renato, additional, Pastorelli, Luca, additional, Manguso, Francesco, additional, Variola, Angela, additional, Di Sario, Antonio, additional, Grossi, Laurino, additional, Ribaldone, Davide Giuseppe, additional, Biscaglia, Giuseppe, additional, Buda, Andrea, additional, Balestrieri, Paola, additional, Mocci, Giammarco, additional, Viscido, Angelo, additional, Di Paolo, Maria Carla, additional, Onali, Sara, additional, Rodino', Stefano, additional, Coletta, Marina, additional, Principi, Mariabeatrice, additional, Miranda, Agnese, additional, Amato, Arnaldo, additional, Bezzio, Cristina, additional, Petruzzellis, Carlo, additional, Mazzuoli, Silvia, additional, Festa, Stefano, additional, Sartini, Alessandro, additional, Fanigliulo, Libera, additional, Gallina, Sara, additional, Bodini, Giorgia, additional, Guidi, Luisa, additional, Savarino, Edoardo, additional, Cappello, Maria, additional, Caprioli, Flavio, additional, Fries, Walter, additional, Scaldaferri, Franco, additional, Castiglione, Fabiana, additional, Massari, Alessandro, additional, Orlando, Ambrogio, additional, and Armuzzi, Alessandro, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results